Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review.

Abstract

Albutrepenonacog-alfa (Idelvion®, CSL Behring) is a recombinant fusion protein in which the recombinant FIX (rFIX) links a recombinant human albumin, extending the half-life of rFIX even beyond 100 hours. In 2016, this drug was approved worldwide for the treatment of pediatric and adult persons with hemophilia B (PWH-B). Its efficacy and safety were described in the PROLONG-9FP program and subsequently confirmed in the real-world practice, even if to date there are not many manuscripts that extensively and completely deal with the use of albutrepenonacog-alfa in daily practice, also evaluating its impact on the quality of life of patients treated with this drug; this review therefore aims to analyze all the publications currently available regarding the real-world use of this extended half-life concentrate, also noting which topics need further study and research.

• Authors: Samantha Pasca, Ezio Zanon
• Journal: Drug design, development and therapy (Drug Des Devel Ther) Vol. 16 Pg. 3109-3116 ( 2022) ISSN: 1177-8881 [Electronic] New Zealand
• PMID: 36132333 (Publication Type: Journal Article, Review)
• Copyright: © 2022 Pasca and Zanon.

Chemical References

• Recombinant Fusion Proteins
• Factor IX
• Serum Albumin, Human

Topics

• Adult
• Child
• Factor IX (therapeutic use)
• Half-Life
• Hemophilia B (drug therapy)
• Humans
• Quality of Life
• Recombinant Fusion Proteins (adverse effects)
• Serum Albumin, Human